iX Biopharma IPO draws strong response
CATALIST-BOUND iX Biopharma, a late-stage specialty pharmaceutical company, drew strong interest from institutional and retail investors for its initial public offering (IPO), with the public offer nearly 25 times subscribed.
At the close of the IPO on Monday, it had received 854 applications for the public offer which represented some 24.7 million offer shares, with application monies amounting to S$11.3 million.
All placement shares have also been fully subscribed for, raising approximately S$29.7 million.
The firm, which is focused on the development and commercialisation of innovative therapies for pain management and male erectile dysfunction, is offering 65.5 million new shares at 46 cents each. Of these, 64.5 million shares are placement shares and one million shares are available for public subscription.
iX Biopharma intends to use the bulk of its net proceeds of S$27.6 million to fund the clinical trials required for the development of its products which are currently in the late stages of clinical development.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Emerging-market optimism dashed by Fed as currencies, bonds sink
LHN warns H1 2024 net profit could decline by 28.6%
iPhone maker Hon Hai’s April sales rise 19% in positive signal
Worsening weather is igniting a US$25 billion market
TikTok tells advertisers: ‘We are not backing down’
EV automakers get reprieve in US tax credit rules